On July 15, 2024, the US Food and Drug Administration (FDA) approved donanemab, a monoclonal antibody developed by Eli Lilly and Company, for the treatment of Alzheimer’s disease. Donanemab, which will be sold under the brand name Kisunla, is intended for individuals with mild cognitive impairment or mild dementia stage of the disease. This approval marks a significant development in the treatment of Alzheimer’s, a condition that affects millions of people worldwide.
The FDA’s decision to approve donanemab was based on clinical trials that studied the medication’s efficacy and safety in patients with mild cognitive impairment or mild dementia. While the treatment has shown promise in slowing down the progression of Alzheimer’s, it is not without risks.
The most common side effects of donanemab include amyloid-related imaging abnormalities, which can cause brain hemorrhages and brain swelling. These conditions can lead to serious complications, such as strokes, seizures, falls, and trouble thinking. According to the clinical trial data, brain hemorrhage and swelling occurred in 36.8% of people taking donanemab, compared to 14.9% of those taking a placebo.
Other common side effects of the medication include headache and allergic reactions. These risks highlight the need for careful consideration and monitoring when prescribing donanemab to patients.
Healthcare providers will need to weigh the potential benefits of the treatment against the potential risks and closely monitor patients for any adverse reactions. The FDA’s approval of donanemab has not been without controversy. Several public interest groups spoke out against the approval of the drug during FDA hearings, citing concerns about its safety and efficacy.
Additionally, most members of the FDA advisory panel had financial conflicts of interest, which has raised questions about the objectivity of the approval process. These concerns underscore the need for ongoing scrutiny and evaluation of donanemab’s safety and effectiveness in real-world settings. Despite these concerns, the approval of donanemab represents a significant step forward in the treatment of Alzheimer’s disease.
The medication has been shown to slow down the progression of the disease in clinical trials, offering new hope to patients and their families. As donanemab becomes available to patients, it will be important to continue monitoring its safety and efficacy, as well as its impact on patients’ quality of life.
Looking ahead, it will be important to watch how donanemab is used in clinical practice and how its safety and efficacy are evaluated in real-world settings. The FDA and other regulatory agencies will need to continue monitoring the medication’s performance and make any necessary adjustments to its labeling or approval status. Additionally, researchers will need to continue studying donanemab and other treatments for Alzheimer’s to better understand their effects and to develop new and more effective therapies.
As the medical community learns more about donanemab and its role in the treatment of Alzheimer’s, patients and their families can expect to have more options and more hope for managing this devastating disease.
